CSL (CSL) AGM 2024 summary
Event summary combining transcript, slides, and related documents.
AGM 2024 summary
18 Jan, 2026Opening remarks and agenda
The meeting was held in a hybrid format, with both in-person and remote participation options, and included procedural instructions for voting and Q&A.
Chair Brian McNamee and Company Secretary Fiona Mead welcomed attendees and outlined the meeting's structure, including online participation and Q&A procedures.
The agenda included board introductions, a business and performance review, formal business items, and a Q&A session.
Financial performance review
Revenue reached US$14.8 billion, up 11% at constant currency; NPATA was US$3 billion, up 15%; net profit after tax up 25%.
Gross profit rose to US$8 billion, maintaining a gross margin above 54%.
Net profit after tax for FY2024 was $2.64 billion, with a final dividend of $2.64 per share.
R&D investment reached US$1.4 billion, up 12% year-on-year; R&D costs at 12% of sales.
Capital expenditure for property, plant, and equipment showed a 31% reduction in FY24.
Board and executive committee updates
Two new non-executive directors, Samantha Lewis and Elaine Sorg, joined the board in 2024; Dr. Brian Daniels to join in December.
Professor Duncan Maskell will retire from the board at the end of the meeting.
Board comprises a diverse group of non-executive directors and the CEO, Paul McKenzie.
CEO Paul McKenzie addressed strategic progress and operational highlights.
The board emphasized the need for global talent and skills in risk management, science, digital, and cybersecurity.
Latest events from CSL
- NPAT fell 80% on US$8.3B revenue as impairments hit, but buyback and guidance held.CSL
H1 202611 Feb 2026 - Growth accelerates with US recovery, new vaccine launches, and global expansion in key markets.CSL
CMD 2025 Part 13 Feb 2026 - Double-digit profit growth, margin expansion, and strong pipeline drive positive FY2025 outlook.CSL
H2 20241 Feb 2026 - R&D pipeline advances with key product filings, innovation in plasma, vaccines, and strong patient focus.CSL
Investor Update19 Jan 2026 - 5% revenue growth, strong Behring/Vifor, Seqirus down, FY2025 double-digit NPATA outlook.CSL
H1 20258 Jan 2026 - FY25 growth, $500M+ savings plan, dividend up 12%, and Seqirus demerger delayed.CSL
AGM 202517 Dec 2025 - High single-digit IG and NPAT growth targeted, driven by efficiency, innovation, and portfolio expansion.CSL
CMD 2025 Part 210 Dec 2025 - Strong FY25 growth, transformation, Seqirus demerger, and robust FY26 outlook.CSL
H2 202523 Nov 2025 - Strong H1 FY25 growth and innovation drive a positive long-term outlook for this biotech leader.CSL
Life Sciences Investor Forum11 Nov 2025